Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Canopy Growth Corporation stock logo
CGC
Canopy Growth
$0.53
-2.7%
$0.78
$0.53
▼
$2.38
$231.15M0.872.60 million shs2.49 million shs
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
$3.65
+1.7%
$4.00
$2.44
▼
$13.15
$360.90M0.982.38 million shs1.19 million shs
Turn Therapeutics Inc. stock logo
TTRX
Turn Therapeutics
$8.55
$11.61
$2.57
▼
$16.45
$261.40MN/A101,465 shs126,359 shs
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
$17.29
-2.3%
$27.42
$16.71
▼
$44.00
$70.96M0.2822,303 shs26,819 shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Canopy Growth Corporation stock logo
CGC
Canopy Growth
-2.35%-12.01%-23.14%-44.63%-48.79%
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
-7.71%+13.97%-10.70%-43.02%-56.27%
Turn Therapeutics Inc. stock logo
TTRX
Turn Therapeutics
-8.56%-12.67%-19.11%-14.41%+113.75%
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
-10.16%-16.48%-33.35%-43.81%-42.56%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Canopy Growth Corporation stock logo
CGC
Canopy Growth
$0.53
-2.7%
$0.78
$0.53
▼
$2.38
$231.15M0.872.60 million shs2.49 million shs
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
$3.65
+1.7%
$4.00
$2.44
▼
$13.15
$360.90M0.982.38 million shs1.19 million shs
Turn Therapeutics Inc. stock logo
TTRX
Turn Therapeutics
$8.55
$11.61
$2.57
▼
$16.45
$261.40MN/A101,465 shs126,359 shs
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
$17.29
-2.3%
$27.42
$16.71
▼
$44.00
$70.96M0.2822,303 shs26,819 shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Canopy Growth Corporation stock logo
CGC
Canopy Growth
-2.35%-12.01%-23.14%-44.63%-48.79%
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
-7.71%+13.97%-10.70%-43.02%-56.27%
Turn Therapeutics Inc. stock logo
TTRX
Turn Therapeutics
-8.56%-12.67%-19.11%-14.41%+113.75%
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
-10.16%-16.48%-33.35%-43.81%-42.56%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Canopy Growth Corporation stock logo
CGC
Canopy Growth
2.25
HoldN/AN/A
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
2.50
Moderate Buy$23.33539.27% Upside
Turn Therapeutics Inc. stock logo
TTRX
Turn Therapeutics
2.67
Moderate Buy$9.005.26% Upside
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
2.78
Moderate Buy$55.83222.92% Upside

Current Analyst Ratings Breakdown

Latest VTVT, SPRY, TTRX, and CGC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/16/2026
Turn Therapeutics Inc. stock logo
TTRX
Turn Therapeutics
Reiterated RatingSell (E+)
11/9/2026
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
UpgradeSell (E+) ➝ Sell (D-)
11/6/2026
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
DowngradeStrong-Buy ➝ Outperform
11/4/2026
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
Reiterated RatingSell (D-)
10/23/2026
Turn Therapeutics Inc. stock logo
TTRX
Turn Therapeutics
UpgradeSell ➝ Hold$10.00
10/16/2026
Canopy Growth Corporation stock logo
CGC
Canopy Growth
DowngradeSell (D-) ➝ Sell (E+)
10/14/2026
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
Reiterated RatingBuy$57.00
10/2/2026
Canopy Growth Corporation stock logo
CGC
Canopy Growth
UpgradeSell (E+) ➝ Sell (D-)
9/24/2026
Turn Therapeutics Inc. stock logo
TTRX
Turn Therapeutics
UpgradeStrong-Buy
9/16/2026
Canopy Growth Corporation stock logo
CGC
Canopy Growth
DowngradeSell (D-) ➝ Sell (E+)
9/14/2026
Turn Therapeutics Inc. stock logo
TTRX
Turn Therapeutics
DowngradeHold ➝ Sell$10.00
(Data available from 11/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Canopy Growth Corporation stock logo
CGC
Canopy Growth
$251.01M0.90N/AN/A$1.10 per share0.48
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
$84.28M4.35N/AN/A($0.12) per share-30.42
Turn Therapeutics Inc. stock logo
TTRX
Turn Therapeutics
N/AN/AN/AN/A$0.19 per shareN/A
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
$1.02M67.97N/AN/A$17.37 per share1.00
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Canopy Growth Corporation stock logo
CGC
Canopy Growth
-$190.29M-$0.51N/AN/AN/A-73.03%-28.21%-17.97%N/A
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
-$171.30M-$2.02N/AN/AN/A-163.64%-453.93%-71.62%N/A
Turn Therapeutics Inc. stock logo
TTRX
Turn Therapeutics
-$3.19M-$0.43N/AN/AN/AN/A-261.87%-70.18%N/A
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
-$26.97M-$0.92N/AN/AN/AN/A-10.15%-8.65%N/A

Latest VTVT, SPRY, TTRX, and CGC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/9/2026Q3 2026
Turn Therapeutics Inc. stock logo
TTRX
Turn Therapeutics
N/A-$0.21N/A-$0.21N/AN/A
11/6/2026Q2 2027
Canopy Growth Corporation stock logo
CGC
Canopy Growth
-$0.02-$0.07-$0.05-$0.07$57.72 million$57.28 million
11/5/2026Q3 2026
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
-$0.3050-$0.36-$0.0550-$0.36$41.99 million$37.71 million
11/5/2026Q3 2026
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
-$1.09-$0.94+$0.15-$0.94$0.33 millionN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Canopy Growth Corporation stock logo
CGC
Canopy Growth
N/AN/AN/AN/AN/A
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
N/AN/AN/AN/AN/A
Turn Therapeutics Inc. stock logo
TTRX
Turn Therapeutics
N/AN/AN/AN/AN/A
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Canopy Growth Corporation stock logo
CGC
Canopy Growth
0.31
2.82
2.20
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
13.72
3.25
3.07
Turn Therapeutics Inc. stock logo
TTRX
Turn Therapeutics
1.01
3.19
3.19
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
N/A
11.19
11.19

Institutional Ownership

CompanyInstitutional Ownership
Canopy Growth Corporation stock logo
CGC
Canopy Growth
3.33%
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
68.16%
Turn Therapeutics Inc. stock logo
TTRX
Turn Therapeutics
N/A
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
17.51%

Insider Ownership

CompanyInsider Ownership
Canopy Growth Corporation stock logo
CGC
Canopy Growth
0.35%
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
33.80%
Turn Therapeutics Inc. stock logo
TTRX
Turn Therapeutics
55.89%
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
5.99%
CompanyEmployeesShares OutstandingFree FloatOptionable
Canopy Growth Corporation stock logo
CGC
Canopy Growth
1,128423.35 million421.87 millionOptionable
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
206100.53 million66.55 millionOptionable
Turn Therapeutics Inc. stock logo
TTRX
Turn Therapeutics
230.57 million13.49 millionOptionable
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
264.01 million3.77 millionNot Optionable

Recent News About These Companies

Comparing vTv Therapeutics (VTVT) and Its Rivals
vTv Therapeutics stock jumps on FDA orphan drug status

New MarketBeat Followers Over Time

Media Sentiment Over Time

Canopy Growth stock logo

Canopy Growth NASDAQ:CGC

$0.53 -0.01 (-2.67%)
Closing price 04:00 PM Eastern
Extended Trading
$0.54 +0.01 (+1.62%)
As of 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in the United States, Canada, Germany, and internationally. It operates through Canada Cannabis, International Markets Cannabis, and Storz & Bickel segments. The company offers dried flower, pre-rolled joints, oils, softgel capsules, infused beverages, edibles comprising gummies, and topical formats, as well as vaporizer devices. It sells its products under the Tweed, 7ACRES, DOJA, Deep Space, HiWay, Maitri, Twd., Vert, Spectrum Therapeutics, Canopy Medical, Storz & Bickel, Martha Stewart, and Wana brands. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation was incorporated in 2009 and is headquartered in Smiths Falls, Canada.

ARS Pharmaceuticals stock logo

ARS Pharmaceuticals NASDAQ:SPRY

$3.65 +0.06 (+1.67%)
Closing price 04:00 PM Eastern
Extended Trading
$3.60 -0.04 (-1.23%)
As of 07:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.

Turn Therapeutics stock logo

Turn Therapeutics NASDAQ:TTRX

$8.55 0.00 (0.00%)
Closing price 04:00 PM Eastern
Extended Trading
$9.15 +0.60 (+6.99%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

We are a pharmaceutical and medical device development company built around a proprietary platform technology designed to enhance drug performance. Our patented mixing process — commercially referred to as PermaFusion™ (“PermaFusion”) — enables stable suspension of polar, water-soluble active pharmaceutical ingredients (“APIs”) in oil-based carriers without the use of emulsifiers. This innovation reduces the quantity of required API inclusion by improving its bioavailability. Reduced API load reduces the likelihood of adverse events. Our proprietary platform has been validated across multiple FDA-cleared medical devices. Our primary development programs focus on dermatological diseases, including moderate to severe eczema and onychomycosis. Our company’s origin is rooted in the personal journey of our founder, who developed a topical ointment to heal his own chronic, treatment-resistant wounds using the PermaFusion platform he developed. His initial formulation, now known as Hexagen (“Hexagen”) suspends certain antimicrobial/anti-inflammatory compounds in petrolatum without known cytotoxicity, irritation or sensitization. This formula has received three FDA clearances and has been utilized extensively in humans, which we believe demonstrates both technical proof of concept and meaningful therapeutic effects. The formula also has been demonstrated to provide anti-inflammatory immunological signaling (IL 36, IL 31, IL 4 inhibition), in-vivo nail penetration with fungal pathogen elimination, and other potential therapeutic benefits. These products are not presently on the market, and we are not currently generating revenue from these devices, as we focus on drug development of our core technology. In addition to our dermatology and wound programs, we are exploring broader applications of our PermaFusion technology. In partnership with a leading global nonprofit organization, we are attempting to develop intranasal vaccines with sufficient thermostability to withstand distribution without deep-freeze. Our goal is to eliminate the need for frozen storage and, thus, enable deployment and delivery to low-resource settings that do not maintain suitable cold storage infrastructure required for administration of modern-day vaccines. Furthermore, if we are successful in this initial program, we believe there may be opportunities to develop additional vaccines in thermostable, intranasal form. By reducing cold-storage infrastructure requirements and therefore enabling standard shipping of such vaccines, we believe intranasal vaccines have the potential to enhance patient uptake by enabling immunization in a broader variety of settings including in clinic, hospital and home-health settings. We believe this initiative highlights our platform’s versatility and its potential to unlock new therapeutic categories beyond dermatology. We have also completed preclinical, in-vivo xenograft studies for herpes zoster ophthalmicus (shingles of the eye) and basal cell carcinoma. A mildly reformulated version of the Hexagen formula was employed for the ocular study and compared this reformulation with placebo as a topical ocular agent intended to reduce viral load of herpes zoster in an animal model. Results obtained showed an 85% reduction in viral load compared to placebo without adverse events. For the basal cell carcinoma xenograft study, the Hexagen formula was compared to both placebo and 5-Fluorouracil (standard of care topical chemotherapy) as a topical treatment intended to reduce basal cell tumor size. The Hexagen formula showed an approximate 29% comparative reduction in tumor size to the placebo and an approximate 20% comparative reduction in tumor size compared to 5-Fluorouracil. We believe these preclinical in-vivo studies suggest meaningful potential in these indications, which we may continue to explore at the conclusion of our lead drug programs. We believe such exploratory results further underscore the potential breadth of opportunity enabled by our platform. We were initially formed on January 6, 2015, as Global Health Solutions, LLC, a Delaware limited liability company. On October 12, 2018, Global Health Solutions, LLC converted to a Delaware corporation under the name Global Health Solutions, Inc., dba Turn Therapeutics. Immediately prior to the effectiveness of the registration statement of which this prospectus forms a part, we intend to change our name to Turn Therapeutics Inc. Our principal executive offices are located in Westlake Village, CA.

vTv Therapeutics stock logo

vTv Therapeutics NASDAQ:VTVT

$17.29 -0.40 (-2.26%)
Closing price 04:00 PM Eastern
Extended Trading
$17.06 -0.23 (-1.33%)
As of 07:32 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

vTv Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes. It is also developing HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 inhibitor, which is in Phase III trial for the treatment of psoriasis, COPD, and atopic dermatitis, as well as TTP-RA, a RAGE antagonist for type 1 diabetes prevention. In addition, the company's other programs include HPP3033, a non-electrophilic therapeutic approach to activating the nuclear factor erythroid 2related factor 2 (Nrf2) pathway for the treatment of chronic diseases associated with oxidative stress; and Azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for glioblastoma, other cancers, and cancer treatment-related conditions. vTv Therapeutics Inc. has license agreements with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593 for therapeutic, prophylactic, and diagnostic application; and Anteris Bio, Inc. to develop and commercialize HPP971, a Nrf2 activator, as well as with Cantex Pharmaceuticals, Inc.; Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; and Novo Nordisk A/S. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.